Novo Nordisk vs. Lupin: Liraglutide Patent Dispute Dismissed in NJ — ANDA Case Resolves in 235 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Lupin Limited |
| Case Number | 1:23-cv-04027 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | July 2023 – March 2024 235 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Generic liraglutide solution for injection, 18 mg/3 ml (6 mg/ml) |
Case Overview
The Parties
⚖️ Plaintiff
Global Danish pharmaceutical leader and the innovator behind liraglutide (Victoza®, Saxenda®), holding an extensive patent portfolio in diabetes and weight management.
🛡️ Defendant
One of India’s largest generic pharmaceutical manufacturers with significant U.S. market operations, routinely challenging branded drug patents through ANDA filings.
Patents at Issue
This case involved two U.S. patents protecting Novo Nordisk’s liraglutide franchise, a GLP-1 analogue widely used in managing Type 2 diabetes and obesity. These patents were central to defending market exclusivity against a generic competitor’s challenge.
- • US 8,114,833 — Covers formulation and pharmaceutical composition aspects of liraglutide-based therapies.
- • US 9,265,893 — Covers additional aspects of liraglutide formulation and therapeutic use.
Developing a GLP-1 analogue?
Check if your formulation or dosage might infringe these or related patents before filing an ANDA.
The Verdict & Legal Analysis
Outcome
The case was **dismissed without prejudice** on March 18, 2024, pursuant to a joint stipulation by both parties. This resolution occurred just 235 days after Novo Nordisk filed suit in the U.S. District Court for the District of New Jersey. Specific settlement terms, licensing arrangements, and any financial consideration were not disclosed in the public record.
Key Legal Issues
The core of the dispute was an ANDA infringement action, triggered by Lupin’s Paragraph IV certification to Novo Nordisk’s patents. Novo Nordisk’s timely filing secured the crucial 30-month stay under the Hatch-Waxman Act, preventing earlier FDA final approval for Lupin’s generic liraglutide. The “dismissed without prejudice” designation is legally significant, meaning no final adjudication of patent validity or infringement was made, and the patents remain presumptively valid.
Importantly, the stipulation explicitly preserved Lupin’s ability to **maintain its Paragraph IV certification**, ensuring the generic manufacturer retains its regulatory pathway to potential final FDA approval without waiving rights to future patent challenges, should commercial or regulatory circumstances evolve.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for GLP-1 formulations.
- View active liraglutide ANDA filers
- Analyze patent expiration timelines for formulation claims
- Review the full litigation history for these patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical formulation or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Liraglutide solution formulations (e.g., 6 mg/ml)
2 Patents at Issue
Covering key formulation aspects
Settlement Focus
Common for GLP-1 disputes, preserving IP
✅ Key Takeaways
Timely Hatch-Waxman filings securing 30-month stays remain the most powerful tool for branded pharmaceutical patent enforcement.
Search related case law →“Dismissed without prejudice” with retained ANDA rights signals a likely structured settlement with confidential market entry terms.
Explore Hatch-Waxman precedents →Frequently Asked Questions
The case involved U.S. Patent Nos. 8,114,833 and 9,265,893, both covering formulation aspects of liraglutide solution for injection.
The parties reached a private resolution. A dismissal without prejudice means no merits ruling was issued — patents remain valid and enforceable, and Lupin’s ANDA pathway was explicitly preserved.
With both patents unchallenged on the merits and remaining in force, other ANDA applicants face the same infringement exposure and should anticipate similar litigation and settlement dynamics.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — U.S. District Court for the District of New Jersey, Case 1:23-cv-04027
- USPTO Patent Center — Patent Details for US 8,114,833 and US 9,265,893
- U.S. Food and Drug Administration (FDA) — ANDA Approvals
- Cornell Legal Information Institute — Hatch-Waxman Act Overview
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.